Spero Therapeutics, INC 10-Q quarterly reports

Spero Therapeutics announces FDA approval for Utebzi and a major collaboration with Innovent for its SP001 program, signaling a strategic shift and potential for future growth.

Spero Therapeutics reports Q3 2025 results, highlighting the successful Phase 3 PIVOT-PO trial for tebipenem HBr and strategic program terminations to focus resources.

Spero Therapeutics reported a reduced net loss in Q2 2025, driven by increased collaboration revenue from GSK and reduced R&D expenses following the successful early halt of its pivotal Phase 3 tebipenem HBr trial, while facing an ongoing SEC investigation and pipeline reprioritization.

Spero Therapeutics announces its Q1 2025 financial results, highlighting ongoing clinical development of tebipenem HBr and addressing concerns about its ability to continue as a going concern.

Spero Therapeutics halts development of SPR720 following disappointing interim Phase 2a results, leading to a strategic restructuring and workforce reduction.

Spero Therapeutics reports a net loss of $30.5 million for the first half of 2024, while advancing its clinical programs and securing additional government funding.

Spero Therapeutics reports a net loss of $12.7 million for the first quarter of 2024, while advancing its clinical programs and receiving a $23.8 million milestone payment from GSK.